News

BRAINTEASER Focus Groups: suitable exploitation routes co-design first online workshop

Published on: 16/02/2022

BRAINTEASER Focus Groups: suitable exploitation routes co-design first online workshop
AI, Horizon 2020

The first out of four BRAINTEASER Focus Groups dedicated to the project’s results exploitation and sustainability, was held on February 1st 2022.

These exploitation Focus Groups aim to broaden the project’s vision on users and market needs, obtaining additional requirements and at accompanying the BRAINTEASER Consortium towards the most suitable results’ sustainability and commercialisation strategy.

The aim of the first online workshop was to offer an overview of the BRAINTEASER project as a whole, shedding light on the clinical apps and tools under development.

By implementing the principles of participatory design, a group of outstanding experts have been engaged in this first gathering and have animated the plenary discussion with views and suggestions to assess and enhance the BRAINTEASER solutions and its exploitation approach.

The panel of speakers was composed of : Patients Associations (Pedro Carrascal – European Multiple Sclerosis Platform President and Patricia Jarabo Blázquez – Fundación Luzón), Medical and scientific experts (Andrea Caffo – EUPALS), ICT Specialists (Peter Wu – ASUSCloud CEO), Policy Regulators  (Daniele Bollati – IMQ Product reviewer and Lead Auditor), Ethical Experts (Sofia Ortet – Nursing School of Coimbra and Vojin Rakic – University of Belgrade · Center for the Study of Bioethics, European Division of the UNESCO Chair of Bioethics, Institute for Social Sciences, Belgarde) and Standardisation Experts (Catherine Chronaki – HL7 Europe Secretary General).

 Watch the workshop recording here:

BRAINTEASER is a data science project that seeks to exploit the value of large clinical datasets integrated with personal and environmental data collected through low-cost sensors, to develop AI-based clinical software and mobile apps to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians.

NEWS​

Related News

New Round Tables announced to drive progress on EHDS and health AI

3 Jul 2025

The European Accessibility Act Is Here. Are You Ready?

2 Jul 2025
Why inclusive design is no longer optional – and how Big Motive can help you lead the way.

DTH-Lab Director: The G7 must act now to address the digital health transformation

2 Jul 2025
As digital platforms increasingly shape health systems and information flows, the G7 must lead in setting global standards to ensure safety, equity an...

InnoHSupport Open Calls

1 Jul 2025
Welcome to the InnoHSupport Open Calls!

Transformative Health Instrument Call 2025

1 Jul 2025
Apply to the Transformative Health Instrument (THI) Call 2025 if you are a growing and innovative healthcare start-up working on solutions that have s...

Longitude Prize on ALS

1 Jul 2025
The £7.5 million (~$10 million) Longitude Prize on ALS incentivises the use of AI-based approaches to transform drug discovery for amyotrophic lateral...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *